RU2003126913A - 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс - Google Patents

3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс Download PDF

Info

Publication number
RU2003126913A
RU2003126913A RU2003126913/04A RU2003126913A RU2003126913A RU 2003126913 A RU2003126913 A RU 2003126913A RU 2003126913/04 A RU2003126913/04 A RU 2003126913/04A RU 2003126913 A RU2003126913 A RU 2003126913A RU 2003126913 A RU2003126913 A RU 2003126913A
Authority
RU
Russia
Prior art keywords
compound
unsubstituted
prodrug
pharmaceutically acceptable
solvate
Prior art date
Application number
RU2003126913/04A
Other languages
English (en)
Inventor
Артур Дж ТЕЙВРЭС (US)
Артур Дж ТЕЙВРЭС
Синти Дж ЭЙКИ (US)
Синтия Дж ЭЙКИ
Ричард В. БОНД (US)
Ричард В. БОНД
Джианпинг ЧАО (US)
Джианпинг ЧАО
Майкл ДВАЙЕР (US)
Майкл ДВАЙЕР
Джоен А. ФЕРРЕЙРА (US)
Джоен А. ФЕРРЕЙРА
Джонатан ПЕЧТЕР (US)
Джонатан ПЕЧТЕР
Джон Дж БОЛДВИН (US)
Джон Дж БОЛДВИН
Бернд КЕЙСЕР (US)
Бернд КЕЙСЕР
Джи ЛИ (CN)
Джи ЛИ
Дж Роберт МЕРРИТТ (US)
Дж Роберт МЕРРИТТ
Кингсли Х. Джр НЕЛЬСОН (US)
Кингсли Х. Джр НЕЛЬСОН
Лаура Л. РОКОС (US)
Лаура Л. РОКОС
Original Assignee
Шеринг Корпорейшн (US)
Шеринг Корпорейшн
Фармакопие Драг Дискавери, Инк. (US)
Фармакопие Драг Дискавери, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шеринг Корпорейшн (US), Шеринг Корпорейшн, Фармакопие Драг Дискавери, Инк. (US), Фармакопие Драг Дискавери, Инк. filed Critical Шеринг Корпорейшн (US)
Publication of RU2003126913A publication Critical patent/RU2003126913A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Claims (38)

1. Соединение формулы
Figure 00000001
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где А означает незамещенную или замещенную арильную или незамещенную или замещенную гетероарильную группу;
В означает
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
;
R2 означает водород, ОН, С(O)ОН, SH, SO2NR7R8, NHC(O)R7, NHSO2NR7R8, NHSO2R7, C(O)NR7R8, C(O)NR7R8, OR13 или незамещенную или замещенную гетероциклическую кислотную функциональную группу;
R3 и R4 являются одинаковыми или разными и независимо выбраны из группы, включающей водород, галоген, алкоксил, ОН, CF3, OCF3, NO2, C(O)R7, C(O)OR7, C(O)NR7R8, SO(t)NR7R8, SO(t)R7, C(O)NR7OR8,
Figure 00000012
, цианогруппу, незамещенный или замещенный алкил, незамещенный или замещенный арил и незамещенный или замещенный гетероарил;
R5 и R6 являются одинаковыми или разными и независимо выбраны из группы, включающей водород, галоген, алкил, алкоксил, CF3, OCF3, NO2, C(O)R7, C(O)OR7, C(O)NR7R8, SO(t)NR7R8, C(O)NR7OR8, цианогруппу и незамещенную или замещенную арильную и незамещенную или замещенную гетероарильную группу;
R7 и R8 являются одинаковыми или разными и независимо выбраны из группы, включающей водород, незамещенный или замещенный алкил, незамещенный или замещенный арил, незамещенный или замещенный алкиларил, незамещенный или замещенный арилалкил, незамещенный или замещенный циклоалкил, карбоксиалкид, аминоалкил, незамещенный или замещенный гетероарил, незамещенный или замещенный гетероарилалкил и незамещенный или замещенный гетероалкиларил, или
R7, R8 и N в указанном NR7R8 и NR7OR8 могут совместно образовывать 3- - 7-членный цикл, и указанный цикл может также содержать от 1 до 3 дополнительных гетероатомов, являющихся циклическими атомами указанного цикла, и указанный цикл может быть незамещенным или содержать в качестве заместителей один или большее количество фрагментов, которые являются одинаковыми или разными и каждый фрагмент независимо выбран из группы, включающей гидроксил, цианогруппу, карбоксил, гидроксиалкил, алкоксил, COR7R8 и аминоалкил;
R9 и R10 являются одинаковыми или разными и независимо выбраны из группы, включающей водород, галоген, CF3, OCF3, NR7R8, NR7C(O)NR7R8, ОН, C(O)OR7, SH, SO(t)NR7R8, SO2R7, NHC(O)R7, NHSO2NR7R8, NHSO2R7, C(O)NR7R8, C(O)NR7OR8, OR13 и незамещенную или замещенную гетероциклическую кислотную функциональную группу;
R13 означает COR7;
R15 означает водород, OR13, или незамещенную или замещенную арильную группу, незамещенную или замещенную гетероарильную группу, незамещенную или замещенную алкиларильную, незамещенную или замещенную циклоалкильную группу и незамещенную или замещенную алкильную; и
t равно 1 или 2.
2. Соединение по п.1, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где А означает
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
и
R11 и R12 являются одинаковыми или разными и независимо означают Н, ОН, галоген, цианогруппу, CF3, CF3О, NR7R8, NR7C(O)NR7R8, C(O)NR7R8, CO2R7, OR7, SO(t)NR7R8, NR7SO(t)R8, COR7 и замещенный или незамещенный арил, замещенный или незамещенный алкил, замещенный или незамещенный арилалкил, замещенный или незамещенный гетероарил, замещенный или незамещенный арилоксил, замещенный или незамещенный гетероарилакил, замещенный или незамещенный гетероциклоалкил, замещенный или незамещенный гидроксиалкил, замещенный или незамещенный алкоксил, алки-ламиноСООалкил, аминоалкоксил, алкоксиаминоалкил или замещенный или незамещенный аминоалкил.
3. Соединение по п.1, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает водород, ОН, NHC(O)R7 или NHSO2R7;
R3 означает SO2NR7R8, C(O)NR7R8, SO2R7, NO2 или цианогруппу;
R4 означает водород, NO2, CF3 или цианогруппу,
R5 означает водород, галоген, NO2, цианогруппу или CF3; и
R6 означает водород или CF3.
4. Соединение по п.2, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где А означает
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
5. Соединение по п.2, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает водород, ОН, NHC(O)R7 или NHSO2R7;
R3 означает SO2NR7R8, C(O)NR7R8, SO2R7, NO2 или цианогруппу;
R4 означает водород, NO2, CF3 или цианогруппу;
R5 означает водород, галоген, цианогруппу, NO2 или CF3; и
R6 означает водород или CF3.
6. Соединение по п.4, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает водород, ОН, NHC(O)R7 или NHSO2R7;
R3 означает SO2NR7R8, C(O)NR7R8, SO2R7, NO2 или цианогруппу;
R4 означает водород, NO2, CF3 или цианогруппу;
R5 означает водород, галоген или CF3; и
R6 означает водород или CF3.
7. Соединение по п.3, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает ОН или NHSO2R7;
R3 означает C(O)NR7R8, NO2 или цианогруппу;
R4 означает водород, NO2 или цианогруппу;
R5 означает водород, Cl или CF3; и
R6 означает водород или CF3.
8. Соединение по п.7, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает ОН;
R3 означает C(O)NR7R8;
R4 означает водород;
R5 означает водород, Cl или CF3; и
R6 означает водород.
9. Соединение по п.5, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает ОН или NHSO2R7;
R3 означает C(O)NR7R8, NO2 или цианогруппу;
R4 означает водород, NO2 или цианогруппу;
R5 означает водород, Cl или CF3; и
R6 означает водород или CF3.
10. Соединение по п.6, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает ОН или NHSO2R7;
R3 означает C(O)NR7R8, NO2 или цианогруппу;
R4 означает водород, NO2 или цианогруппу;
R5 означает водород, Cl или CF3; и
R6 означает водород или CF3.
11. Соединение по п.9, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает ОН;
R3 означает C(O)NR7R8;
R4 означает водород;
R5 означает водород, Cl или CF3; и
R6 означает водород.
12. Соединение по п.10, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где R2 означает ОН;
R3 означает C(O)NR7R8;
R4 означает водород;
R5 означает водород, Cl или CF3; и
R6 означает водород.
13. Соединение по п.1, его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы;
где А и В являются такими, как указанно в представленной ниже таблице:
Пример А В 20
Figure 00000043
Figure 00000044
 36
Figure 00000045
Figure 00000046
 
Пример А В 37
Figure 00000047
Figure 00000048
 45
Figure 00000049
Figure 00000050
 49
Figure 00000051
Figure 00000052
 50
Figure 00000053
Figure 00000054
 63
Figure 00000055
Figure 00000056
 64
Figure 00000057
Figure 00000058
 65
Figure 00000059
Figure 00000060
 66
Figure 00000061
Figure 00000062
 
Пример А В 71
Figure 00000063
Figure 00000064
 74
Figure 00000065
Figure 00000066
 89
Figure 00000067
Figure 00000068
 90
Figure 00000069
Figure 00000070
 96
Figure 00000071
Figure 00000072
  
Figure 00000073
Figure 00000074
  
Figure 00000075
Figure 00000076
 
Пример А В  
Figure 00000077
Figure 00000078
14. Соединение по п.13 формулы
Figure 00000079
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
15. Соединение по п.13 формулы
Figure 00000080
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
16. Соединение по п.13 формулы
Figure 00000081
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
17. Соединение по п.13 формулы
Figure 00000082
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
18. Соединение по п.13 формулы
Figure 00000083
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
19. Соединение по п.13 формулы
Figure 00000084
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
20. Соединение по п.13 формулы
Figure 00000085
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
21. Соединение по п.13 формулы
Figure 00000086
его пролекарственная форма или фармацевтически приемлемая соль, сольват или изомер указанного соединения или указанной пролекарственной формы.
22. Фармацевтическая композиция, включающая соединение по п.1, его пролекарственную форму или фармацевтически приемлемую соль, сольват или изомер указанного соединения или указанной пролекарственной формы и его фармацевтически приемлемый носитель.
23. Способ лечения опосредуемого хемокином заболевания, в котором хемокин связывается с рецептором CXCR2 и/или CXCR1 млекопитающего, который включает введение пациенту, нуждающемуся в нем, терапевтически эффективного количества соединения по п.1 или его фармацевтически приемлемой соли, сольвата или изомера указанного соединения или указанной пролекарственной формы.
24. Способ лечения опосредуемого хемокином заболевания, в котором хемокин связывается с рецептором СХС млекопитающего, который включает введение пациенту, нуждающемуся в нем, терапевтически эффективного количества соединения по п.1 или его фармацевтически приемлемой соли, сольвата или изомера указанного соединения или указанной пролекарственной формы.
25. Способ по п.23, в котором опосредуемое хемокином заболевание выбирается из группы, включающей псориаз, атопический дерматит, астму, хроническое обструктивное заболевание легких, респираторное заболевание взрослых, артрит, воспалительное заболевание кишечника, болезнь Крона, язвенный колит, септический шок, эндотоксический шок, грамотрицательный сепсис, токсический шок, инсульт, реперфузионное поражение сердца и почек, гломерулонефрит или тромбоз, болезнь Альцгеймера, реакция "трансплантант против хозяина", отторжение аллотрансплантата, малярию, острый респираторный дистресс-синдром, реакция гиперчувствительности замедленного типа, атеросклероз и ишемию головного мозга и ишемическую болезнь сердца.
26. Способ лечения рака, который включает введение пациенту, нуждающемуся в нем, терапевтически эффективного количества соединения по п.1 или его фармацевтически приемлемой соли, сольвата или изомера указанного соединения или указанной пролекарственной формы.
27. Способ по п.26, который дополнительно включает введение пациенту, по крайней мере, одного противоракового агента и/или проведение лучевой терапии.
28. Способ по п.27, в котором противораковый агент выбирается из группы, включающей алкилирующие препараты, антиметаболиты, природные продукты и их производные, гормоны, антигормоны, антиангиогенные агенты, стероиды и синтетические препараты.
29. Способ ингибирования ангиогенеза, который включает введение пациенту, нуждающемуся в нем, антиангиогенного количества соединения по п.1 или его фармацевтически приемлемой соли, сольвата или изомера указанного соединения или указанной пролекарственной формы.
30. Способ по п.29, который дополнительно включает введение пациенту, по крайней мере, одного известного антиангиогенного препарата.
31. Способ по п.30, в котором известный антиангиогенный агент выбирается из группы, включающей маримастат, AG3340, Col-3, неовастат, BMS-275291, талидомид, скваламин, эндостатин, SU-5416, SU-6668, альфа-интерферон, антитела Anti-VEGF, EMD121974, CAI, интерлейкин-12, IM862, фактор тромбоцитов-4, витаксин, ангиостатин, сурамин, TNP-470, РТК-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, ингибиторы киназы рецептора VEGF, таксотер и таксол.
32. Способ лечения заболевания, выбранного из группы, включающей гингивит, заболевание, вызванное респираторными вирусами, вирусами герпеса, вирусами гепатита, ВИЧ, вирусом, ассоциированным с саркомой Капоши, и атеросклероз, который включает введение пациенту, нуждающемуся в нем, терапевтически эффективного количества соединения по п.1 или его фармацевтически приемлемой соли, сольвата или изомера указанного соединения или указанной пролекарственной формы.
33. Способ по п.23, в котором опосредуемое хемокином заболевание представляет собой ангиогенное заболевание глаз.
34. Способ по п.33, в котором ангиогенное заболевание глаз выбирается из группы, включающей воспаление глаз, ретинопатию недоношенных, диабетическую ретинопатию, макулярную дегенерацию, преимущественно “мокрого” типа, и неоваскуляризацию роговицы.
35. Способ по п.26, в котором типом раковой опухоли является меланома, рак желудка или немелкоклеточный рак легких.
36. Способ по п.35, который дополнительно включает введение пациенту, по крайней мере, одного противоракового агента и/или проведение лучевой терапии.
37. Способ по п.36, в котором противораковый агент выбирается из группы, включающей алкилирующие агенты, антиметаболиты, природные продукты и их производные, гормоны, антигормоны, антиангиогенные агенты, стероиды и синтетические агенты.
38. Способ по п.37, в котором антиангиогенный агент выбирается из группы, включающей маримастат, AG3340, Col-3, неовастат, BMS-275291, талидомид, скваламин, эндостатин, SU-5416, SU-6668, альфа-интерферон, антитела Anti-VEGF, EMD121974, CAI, интерлейкин-12, IM862, фактор тромбоцитов-4, витаксин, ангиостатин, сурамин, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, ингибиторы киназы рецептора VEGF, таксотер и таксол.
RU2003126913/04A 2001-02-02 2002-02-01 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс RU2003126913A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26595101P 2001-02-02 2001-02-02
US60/265.951 2001-02-02

Publications (1)

Publication Number Publication Date
RU2003126913A true RU2003126913A (ru) 2005-03-10

Family

ID=23012553

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003126913/04A RU2003126913A (ru) 2001-02-02 2002-02-01 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс

Country Status (20)

Country Link
US (1) US20030097004A1 (ru)
EP (1) EP1355875A1 (ru)
JP (1) JP2004529911A (ru)
KR (1) KR20030090629A (ru)
CN (1) CN1575273A (ru)
AU (1) AU2002303084B2 (ru)
BR (1) BR0206968A (ru)
CA (1) CA2436351A1 (ru)
CZ (1) CZ20032098A3 (ru)
EC (1) ECSP034712A (ru)
HU (1) HUP0304047A2 (ru)
IL (1) IL156793A0 (ru)
MX (1) MXPA03006950A (ru)
NO (1) NO20033424L (ru)
NZ (1) NZ527947A (ru)
PL (1) PL367534A1 (ru)
RU (1) RU2003126913A (ru)
SK (1) SK9782003A3 (ru)
WO (1) WO2002076926A1 (ru)
ZA (1) ZA200305881B (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037916B2 (en) * 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7475478B2 (en) 2001-06-29 2009-01-13 Kva, Inc. Method for manufacturing automotive structural members
EP1434775A1 (en) 2001-10-12 2004-07-07 Schering Corporation 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
CA2479126C (en) 2002-03-18 2011-11-15 Schering Corporation Combination treatments for chemokine-mediated diseases
WO2003099223A2 (en) * 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
EP1545527A1 (en) 2002-06-28 2005-06-29 Novartis AG Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
CA2501535A1 (en) * 2002-10-09 2004-04-22 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
KR20050061586A (ko) * 2002-10-31 2005-06-22 셀진 코포레이션 황반 변성의 치료를 위한 조성물
WO2004069829A1 (en) * 2003-01-10 2004-08-19 Pharmacopeia Drug Discovery, Inc. (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis
CN101514168B (zh) * 2003-04-18 2014-02-26 默沙东公司 苯甲酰胺取代的二氧代环丁烯的合成
US20070042997A1 (en) * 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
CA2550540A1 (en) * 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
JP2007537272A (ja) 2004-05-12 2007-12-20 シェーリング　コーポレイション Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1674457B1 (en) * 2004-12-23 2009-06-03 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
DE102005001053A1 (de) * 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
US7718678B2 (en) 2005-06-29 2010-05-18 Schering Corporation Di-substituted oxadiazoles as CXC-chemokine receptor ligands
WO2007005403A1 (en) 2005-06-29 2007-01-11 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
DE102005035741A1 (de) * 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
DE102005035742A1 (de) * 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
AU2007206016A1 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
AU2007240365B2 (en) * 2006-04-21 2011-12-15 Glaxosmithkline Llc IL-8 receptor antagonists
WO2007124423A2 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
EP2021316A1 (en) * 2006-05-26 2009-02-11 Abbott Laboratories Inhibitors of polo-like kinases
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
PE20080943A1 (es) * 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
WO2010131145A1 (en) * 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
KR101428346B1 (ko) 2009-09-28 2014-08-07 에프. 호프만-라 로슈 아게 벤즈옥사제핀 ｐｉ3ｋ 억제 화합물 및 사용 방법
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR20200037857A (ko) 2017-08-14 2020-04-09 알러간, 인코포레이티드 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도
CN111867579B (zh) 2018-01-08 2023-11-24 凯莫森特里克斯股份有限公司 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
CN108660203A (zh) * 2018-05-18 2018-10-16 大连医科大学附属第医院 Cxcr2基因在心脏相关疾病中的用途
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN112851635B (zh) * 2019-11-28 2022-09-16 中国医学科学院药物研究所 环状砜类化合物及其制备方法、用途和药物组合物
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1531943A (fr) * 1966-07-28 1968-07-05 Huels Chemische Werke Ag Procédé pour stabiliser des poly-acétals macromoléculaires
DE2638855C3 (de) * 1976-08-28 1980-04-24 Chemische Werke Huels Ag, 4370 Marl Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
US5849403A (en) * 1995-09-13 1998-12-15 Kabushiki Kaisha Toshiba Organic thin film device
US6150042A (en) * 1996-12-09 2000-11-21 Toyo Ink Manufacturing Co., Ltd. Material for organoelectro-luminescence device and use thereof
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6303238B1 (en) * 1997-12-01 2001-10-16 The Trustees Of Princeton University OLEDs doped with phosphorescent compounds
JP2998737B2 (ja) * 1998-03-13 2000-01-11 日本電気株式会社 周辺機器用電源制御装置
EP1029909A4 (en) * 1998-09-09 2007-01-10 Idemitsu Kosan Co ORGANIC ELECTROLUMINESCENT DEVICE AND PHENYLENE DERIVATIVES
EP1117633B1 (en) * 1998-10-02 2002-09-18 Neurosearch A/S Diaminocyclobutene-3,4-dione derivatives, their preparation and use
AU761407B2 (en) * 1998-12-16 2003-06-05 Bayer Aktiengesellschaft New biphenyl and biphenyl-analogous compounds as integrin antagonists
JP3924648B2 (ja) * 1999-11-02 2007-06-06 ソニー株式会社 有機電界発光素子
EP1173049B1 (en) * 2000-02-02 2015-05-27 Mitsubishi Chemical Corporation Organic electroluminescent element
AR033803A1 (es) * 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
KR20010104215A (ko) * 2000-05-12 2001-11-24 야마자끼 순페이 발광장치 제작방법
CZ20023915A3 (cs) * 2000-05-30 2003-04-16 Smithkline Beecham Corporation Antagonisté IL-8 receptoru
SG148030A1 (en) * 2000-12-28 2008-12-31 Semiconductor Energy Lab Luminescent device
TW545080B (en) * 2000-12-28 2003-08-01 Semiconductor Energy Lab Light emitting device and method of manufacturing the same
EP1357909B1 (en) * 2001-01-16 2009-01-07 Smithkline Beecham Corporation Il-8 receptor antagonists
TW518909B (en) * 2001-01-17 2003-01-21 Semiconductor Energy Lab Luminescent device and method of manufacturing same
TW519770B (en) * 2001-01-18 2003-02-01 Semiconductor Energy Lab Light emitting device and manufacturing method thereof
US6765348B2 (en) * 2001-01-26 2004-07-20 Xerox Corporation Electroluminescent devices containing thermal protective layers
SG118110A1 (en) * 2001-02-01 2006-01-27 Semiconductor Energy Lab Organic light emitting element and display device using the element
TWI225312B (en) * 2001-02-08 2004-12-11 Semiconductor Energy Lab Light emitting device
US20030010288A1 (en) * 2001-02-08 2003-01-16 Shunpei Yamazaki Film formation apparatus and film formation method
US7432116B2 (en) * 2001-02-21 2008-10-07 Semiconductor Energy Laboratory Co., Ltd. Method and apparatus for film deposition
SG118118A1 (en) * 2001-02-22 2006-01-27 Semiconductor Energy Lab Organic light emitting device and display using the same

Also Published As

Publication number Publication date
US20030097004A1 (en) 2003-05-22
CZ20032098A3 (cs) 2004-01-14
CA2436351A1 (en) 2002-10-03
AU2002303084B2 (en) 2006-05-25
ECSP034712A (es) 2003-09-24
HUP0304047A2 (hu) 2004-04-28
CN1575273A (zh) 2005-02-02
SK9782003A3 (en) 2004-01-08
NZ527947A (en) 2005-10-28
WO2002076926A1 (en) 2002-10-03
JP2004529911A (ja) 2004-09-30
ZA200305881B (en) 2005-01-26
BR0206968A (pt) 2004-03-09
NO20033424L (no) 2003-09-30
KR20030090629A (ko) 2003-11-28
PL367534A1 (en) 2005-02-21
EP1355875A1 (en) 2003-10-29
MXPA03006950A (es) 2003-11-18
IL156793A0 (en) 2004-02-08
NO20033424D0 (no) 2003-07-31

Similar Documents

Publication Publication Date Title
RU2003126913A (ru) 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс
JP2004529911A5 (ru)
RU2005106871A (ru) Ингибиторы протеинкиназ и их применение
RU2007120687A (ru) Новые антраниламидопиридинмочевины в качестве ингибиторов киназы васкулярного эндотелиального фактора роста (vegf)
US11834443B2 (en) Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
JPWO2021092115A5 (ru)
DE3220262A1 (de) Carboximidderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
IE69971B1 (en) Pyridinium derivatives their production and use
JPH04217956A (ja) 新規デオキシノジリマイシン誘導体、その製造方法及び薬剤としてのそれらの使用
CH643549A5 (de) N-(trimethoxybenzyl)-n'-phenylpiperazine.
JPS63225355A (ja) １，４−ジヒドロピリジン誘導体
EP0018360B1 (de) N-(5-Methoxybentofuran-2-ylcarbonyl)-N'-benzylpiperazin und Verfahren zu dessen Herstellung
JPH09507672A (ja) ニトロキシ基含有ベンジルアミン誘導体及び循環器疾患並びに眼内圧増加の治療のためのその使用
JPH0345042B2 (ru)
JPS5988475A (ja) 新規な２−アミノ−５−アミノメチル−２−オキサゾリン、その製法及び治療への適用
Lewis et al. Novel analgesics and molecular rearrangements in the morphine–thebaine group. Part XIX. Further Diels–Alder adducts of thebaine
US2534236A (en) 8-haloxanthine salts of dialkylaminoalkyl 0-benzylphenyl ethers and the production thereof
JPS60172972A (ja) 新規な５位置換５，１０−ジヒドロ−１１Ｈ−ジベンゾ〔ｂ，ｅ〕〔１，４〕ジアゼピン−１１−オンの製造法
DE2631080A1 (de) 4-(3-substituierte-amino-2-hydroxy) propoxy-2-alkyl-isocarbostyril-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US3308133A (en) Novel alkylene diamine derivatives
JPS58201765A (ja) ジヒドロピリジン誘導体，その製造法および用途
JPH0138114B2 (ru)
US3015658A (en) Process for the preparation of new
JPH03145464A (ja) 光学活性１，４―ジヒドロピリジン誘導体
DE2127129C3 (de) Neue l-(3',4\5'-Trimethoxycinnamoyl)-4-(alkoxycarbonyläthyl)piperazinderivate und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20071005